SCI时时刷

search
+
Insurance coverage and access to gynecologic oncology: Where are we now
Update your browser to view ScienceDirect. ...
Oncologic and fertility outcomes in patients with juvenile granulosa cell tumor - a retrospective single centre analysis
Update your browser to view ScienceDirect. ...
Clinical trial enrollment during first course of gynecologic cancer treatment and survival
Update your browser to view ScienceDirect. ...
Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer
Update your browser to view ScienceDirect. ...
A randomized controlled trial of an online support group addressing psychosexual distress among women treated for gynecologic cancer
Update your browser to view ScienceDirect. ...
Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer
Update your browser to view ScienceDirect. ...
Insurance coverage and access to gynecologic oncology: Where are we are now
Update your browser to view ScienceDirect. ...
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
Update your browser to view ScienceDirect. ...
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer
Update your browser to view ScienceDirect. ...
Cost-effectiveness of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a US payer perspective
Update your browser to view ScienceDirect. ...
Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial
Update your browser to view ScienceDirect. ...
Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer
Update your browser to view ScienceDirect. ...
What happens after menopause? (WHAM): Impact of risk-reducing salpingo-oophorectomy on depressive and anxiety symptoms at 24 months
Update your browser to view ScienceDirect. ...
Evolutionary pathways in early-stage, non-myoinvasive endometrioid endometrial cancers of no specific molecular profile
Update your browser to view ScienceDirect. ...
KRAS mutations in endometrial cancers: Possible prognostic and treatment implications
Update your browser to view ScienceDirect. ...
Disparities in ovarian cancer survival among ethnic Asian American populations, 2006–2020
Update your browser to view ScienceDirect. ...
Too much of a good thing? Projecting the need for gynecologic oncologists over the next 20 years
Update your browser to view ScienceDirect. ...
Biobehavioral predictors of mood, pain, fatigue, and insomnia in endometrial cancer survivors
Update your browser to view ScienceDirect. ...
Standard of care treatment for stage IVB cervical cancer: A systematic review and meta-analysis
Update your browser to view ScienceDirect. ...
Molecular classification in fertility-sparing treatment of early-stage endometrial cancer: A potential tool for optimizing patient selection
Update your browser to view ScienceDirect. ...
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha–expressing recurrent ovarian cancer: An integrated safety summary
Update your browser to view ScienceDirect. ...
Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer
Update your browser to view ScienceDirect. ...
Trends in brachytherapy in utilization for vaginal cancer in the United States from 2004 to 2021
Update your browser to view ScienceDirect. ...
Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016–01)
Update your browser to view ScienceDirect. ...
Adjuvant therapy de-escalation for stage I uterine leiomyosarcoma: A systematic review and meta-analysis
Update your browser to view ScienceDirect. ...
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study
Update your browser to view ScienceDirect. View recommended browsers. Request details: Request ID: 8d77626bce95fb48-...
Cold ischemia time and formalin fixation time in endometrial cancer: Should breast cancer guidelines for preanalytical variables be applied to hysterectomy specimens?
Update your browser to view ScienceDirect. View recommended browsers. Request details: Request ID: 8d77625e3ae86803-...
What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 24 months after premenopausal risk-reducing salpingo-oophorectomy (RRSO)
Update your browser to view ScienceDirect. View recommended browsers. Request details: Request ID: 8d7762581bd7253c-...
Five-year quality-of-life assessment by urinary diversion type after pelvic Exenterations
Update your browser to view ScienceDirect. View recommended browsers. Request details: Request ID: 8d776251cd6467ab-...
Less is more? Comparison between genomic profiling and immunohistochemistry-based models in endometrial cancer molecular classification: A multicenter, retrospective, propensity-matched survival analysis
Update your browser to view ScienceDirect. View recommended browsers. Request details: Request ID: 8d5cf2c9cf69ce78-...
阅读更多
format_indent_increase